课题基金 / 基金详情

Development of Reversible Inhibitors of Factor XIa

Development of Reversible Inhibitors of Factor XIa
XIa 因子可逆抑制剂的开发
批准号:
nhmrc : 1024982
负责人:
A/Pr Mark Coster
金额:
$29.63万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2012
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2012-01-01 至 2014-12-31

项目摘要

项目成果

A/Pr Mark Coster的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Blood usually clots in response to injury, but unwanted clots can cause thrombosis, as well as leading to stroke and heart disease. Existing drugs to treat thrombosis suffer from drawbacks such as invasive monitoring, interaction with diet and other medicines, and bleeding complications. New drugs are clearly needed. Our expert group of researchers will discover new anti-thrombotic compounds based upon our previous identification of natural products with anticoagulant properties.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Evaluation of Novel Pyrrolo/Iminoquinone Antimalarial Compounds
  • 批准号:
    nhmrc : 1024314
  • 项目类别:
    Project Grants
  • 资助金额:
    $40.96万
  • 财政年份:
    2012
  • 负责人:
    A/Pr Mark Coster
  • 依托单位:
国内基金
海外基金
温敏不育突变体(reversible male sterile)育性转换机制的研究
  • 批准号:
    31770348
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2017
  • 负责人:
    朱骏
  • 依托单位: